within Pharmacolibrary.Drugs.C_CardiovascularSystem.C02D_ArteriolarSmoothMuscleAgentsActingOn.C02DG01_Pinacidil;

model Pinacidil
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.35,
    Cl = 1.5277777777777777e-05,
    adminDuration = 600,
    adminMass = 10 / 1000000,
    adminCount = 1,
    Vd = 0.15,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.0008333333333333334,
    Tlag = 600);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Pinacidil</td></tr><tr><td>ATC code:</td><td>C02DG01</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>10</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>150</td><td>L</td></tr>
    <tr><td>clearance:</td><td>55</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Pinacidil is a vasodilator drug acting as an ATP-sensitive potassium channel opener. It was primarily developed for the management of hypertension but is now largely obsolete and not in widespread clinical use. Pinacidil causes relaxation of vascular smooth muscle, leading to decreased blood pressure.</p><h4>Pharmacokinetics</h4><p>No published clinical pharmacokinetic data found for pinacidil in humans. Parameters are estimated based on its chemical class, typical drug characteristics, and secondary references.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.C.C02DG01 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Pinacidil;
